FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947200617> ?p ?o ?g. }

• W2947200617 abstract "To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and the Juvenile Arthritis Disease Activity Score (JADAS). Efficacy data are reported as responder analyses using a hybrid method for missing data imputation and as observed cases. Safety assessments included treatment-emergent adverse events (TEAEs). Out of 127 patients originally enrolled in CLIPPER, 109 (86%) entered CLIPPER2. After 6 years of trial participation (2 years in CLIPPER and 4 years in CLIPPER2), 41 (32%) patients were still taking ETN, 13 (11%) entered the treatment withdrawal phase after achieving low/inactive disease (of whom 7 had to restart ETN), 36 (28%) discontinued treatment for other reasons but are still being observed, and 37 (29%) discontinued treatment permanently. According to the hybrid imputation analysis, proportions of patients achieving JIA ACR90, JIA ACR100, and JADAS inactive disease after the initial 2 years of treatment were 58%, 48%, and 32%, respectively. After the additional 4 years, those proportions in patients who remained in the trial were 46%, 35%, and 24%. Most frequently reported TEAEs [n (%), events per 100 patient-years] were headache [28 (22%), 5.3], arthralgia [24 (19%), 4.6], and pyrexia [20 (16%), 3.8]. Number and frequency of TEAEs, excluding infections and injection site reactions, decreased over the 6-year period from 193 and 173.8, respectively, during year 1 to 37 and 61.3 during year 6. A single case of malignancy (Hodgkin’s lymphoma) and no cases of active tuberculosis, demyelinating disorders, or deaths were reported. Open-label etanercept treatment for up to 6 years was safe, well tolerated, and effective in patients with eoJIA, ERA, and PsA. ClinicalTrials.gov: CLIPPER, NCT00962741 , registered 20 August, 2009, CLIPPER2, NCT01421069 , registered 22 August, 2011." @default.
• W2947200617 created "2019-06-07" @default.
• W2947200617 creator A5006317525 @default.
• W2947200617 creator A5009421355 @default.
• W2947200617 creator A5012015082 @default.
• W2947200617 creator A5020169008 @default.
• W2947200617 creator A5020603336 @default.
• W2947200617 creator A5021469305 @default.
• W2947200617 creator A5027612338 @default.
• W2947200617 creator A5031464437 @default.
• W2947200617 creator A5037623865 @default.
• W2947200617 creator A5046909004 @default.
• W2947200617 creator A5047209301 @default.
• W2947200617 creator A5053719643 @default.
• W2947200617 creator A5055180780 @default.
• W2947200617 creator A5061798965 @default.
• W2947200617 creator A5062345423 @default.
• W2947200617 creator A5065884210 @default.
• W2947200617 creator A5069508163 @default.
• W2947200617 creator A5077451775 @default.
• W2947200617 creator A5077663891 @default.
• W2947200617 creator A5078850011 @default.
• W2947200617 creator A5080140512 @default.
• W2947200617 creator A5089399042 @default.
• W2947200617 creator A5091020794 @default.
• W2947200617 creator A5091060565 @default.
• W2947200617 date "2019-05-23" @default.
• W2947200617 modified "2023-10-17" @default.
• W2947200617 title "Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial" @default.
• W2947200617 cites W1969936299 @default.
• W2947200617 cites W1998366883 @default.
• W2947200617 cites W2017213437 @default.
• W2947200617 cites W2024714476 @default.
• W2947200617 cites W2024860303 @default.
• W2947200617 cites W2027727451 @default.
• W2947200617 cites W2028698702 @default.
• W2947200617 cites W2033881274 @default.
• W2947200617 cites W2044015582 @default.
• W2947200617 cites W2050675596 @default.
• W2947200617 cites W2070021262 @default.
• W2947200617 cites W2073700972 @default.
• W2947200617 cites W2075591761 @default.
• W2947200617 cites W2080685621 @default.
• W2947200617 cites W2087769239 @default.
• W2947200617 cites W2104175901 @default.
• W2947200617 cites W2104307666 @default.
• W2947200617 cites W2105600582 @default.
• W2947200617 cites W2110217426 @default.
• W2947200617 cites W2111166972 @default.
• W2947200617 cites W2114155762 @default.
• W2947200617 cites W2123552734 @default.
• W2947200617 cites W2124481925 @default.
• W2947200617 cites W2130978342 @default.
• W2947200617 cites W2134389576 @default.
• W2947200617 cites W2135974703 @default.
• W2947200617 cites W2138049450 @default.
• W2947200617 cites W2138181327 @default.
• W2947200617 cites W2152334103 @default.
• W2947200617 cites W2168958406 @default.
• W2947200617 cites W2221264044 @default.
• W2947200617 cites W2312982528 @default.
• W2947200617 cites W2328780927 @default.
• W2947200617 cites W2337498254 @default.
• W2947200617 cites W2346701512 @default.
• W2947200617 cites W2615525468 @default.
• W2947200617 cites W2786447865 @default.
• W2947200617 cites W4255497843 @default.
• W2947200617 doi "https://doi.org/10.1186/s13075-019-1916-9" @default.
• W2947200617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6533709" @default.
• W2947200617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31122296" @default.
• W2947200617 hasPublicationYear "2019" @default.
• W2947200617 type Work @default.
• W2947200617 sameAs 2947200617 @default.
• W2947200617 citedByCount "28" @default.
• W2947200617 countsByYear W29472006172019 @default.
• W2947200617 countsByYear W29472006172020 @default.
• W2947200617 countsByYear W29472006172021 @default.
• W2947200617 countsByYear W29472006172022 @default.
• W2947200617 countsByYear W29472006172023 @default.
• W2947200617 crossrefType "journal-article" @default.
• W2947200617 hasAuthorship W2947200617A5006317525 @default.
• W2947200617 hasAuthorship W2947200617A5009421355 @default.
• W2947200617 hasAuthorship W2947200617A5012015082 @default.
• W2947200617 hasAuthorship W2947200617A5020169008 @default.
• W2947200617 hasAuthorship W2947200617A5020603336 @default.
• W2947200617 hasAuthorship W2947200617A5021469305 @default.
• W2947200617 hasAuthorship W2947200617A5027612338 @default.
• W2947200617 hasAuthorship W2947200617A5031464437 @default.
• W2947200617 hasAuthorship W2947200617A5037623865 @default.
• W2947200617 hasAuthorship W2947200617A5046909004 @default.
• W2947200617 hasAuthorship W2947200617A5047209301 @default.
• W2947200617 hasAuthorship W2947200617A5053719643 @default.
• W2947200617 hasAuthorship W2947200617A5055180780 @default.
• W2947200617 hasAuthorship W2947200617A5061798965 @default.
• W2947200617 hasAuthorship W2947200617A5062345423 @default.
• W2947200617 hasAuthorship W2947200617A5065884210 @default.
• W2947200617 hasAuthorship W2947200617A5069508163 @default.
• W2947200617 hasAuthorship W2947200617A5077451775 @default.
• W2947200617 hasAuthorship W2947200617A5077663891 @default.
• W2947200617 hasAuthorship W2947200617A5078850011 @default.

• next